RxDoctor Payments Data

Radhika Kotha, MD

Family Medicine · Pittsburgh, PANPI 1740418813

Payments from drug & device makers

$857in general payments, 2019–2025

Across 45 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$247
  • Novo Nordisk$167
  • Pfizer$111
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55
  • AstraZeneca$51
  • GSK$40
  • plus $188 from 8 others

What the payments were for

  • Food & beverage$857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$857 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,459
Medicare patients
186
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$161,364
EliquisApixaban133$136,198
JardianceEmpagliflozin85$81,028
JanuviaSitagliptin Phosphate92$78,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$45,355
XareltoRivaroxaban35$45,335
Spiriva RespimatTiotropium Bromide65$40,111
TrulicityDulaglutide36$36,620
MounjaroTirzepatide28$28,963
Breo ElliptaFluticasone/Vilanterol56$25,373
MyrbetriqMirabegron27$18,686
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$15,216
TradjentaLinagliptin13$14,271
FarxigaDapagliflozin Propanediol15$12,379
Atorvastatin Calcium1,087$12,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$167$161,364150 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta$18$150,626189 claims
PfizerEliquis$111$136,198133 claims
MerckJanuvia$22$78,15692 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$40$75,952129 claims
Lilly USA, LLCTrulicity, Mounjaro$30$65,58364 claims
AstraZenecaFarxiga, Brilinta$51$18,03627 claims
AbbVieLinzess, Synthroid$247$10,33259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →